In a report released yesterday, Brian Abrahams from RBC Capital reiterated a Buy rating on Intra-Cellular Therapies (NASDAQ: ITCI), with a price target of $35. The company’s shares closed yesterday at $21.84.
According to TipRanks.com, Abrahams is a 5-star analyst with an average return of 12.2% and a 55.8% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Proteostasis Therapeutics Inc, Alder Biopharmaceuticals, and Karyopharm Therapeutics.
Currently, the analyst consensus on Intra-Cellular Therapies is a Strong Buy with an average price target of $30.50, a 39.7% upside from current levels. In a report issued on July 23, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $28 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $25.82 and a one-year low of $10.25. Currently, Intra-Cellular Therapies has an average volume of 353.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Intra-Cellular Therapies, Inc. is a biopharmaceutical company, which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. Its lead product candidate, I
